United Laboratories International (HKG:3933) said Ceftriaxone Sodium for Injection has received approval from China's National Medical Products Administration as having passed the consistency evaluation of quality and efficacy for generic drugs, a Friday filing with the Hong Kong bourse said.
The drug was submitted by the Zhongshan Branch of Zhuhai United Laboratories, a unit of the intermediate and finished products and bulk medicine company.
The drug is an antibiotic for the treatment of infections caused by sensitive pathogens, including respiratory tract, abdominal, renal and urinary tract, reproductive system, and preoperative infections.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。